• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8/7/25 4:03:40 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STXS alert in real time by email
    false 0001289340 0001289340 2025-08-07 2025-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(D) of the Securities Exchange Act Of 1934

     

    Date of report (Date of earliest event reported): August 7, 2025

     

    STEREOTAXIS, INC.

     

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

     

    (State or Other Jurisdiction of Incorporation)

     

    001-36159   94-3120386
    (Commission File Number)   (IRS Employer Identification No.)

     

    710 North Tucker Boulevard, Suite 110, St. Louis, Missouri   63101
    (Address of Principal Executive Offices)   (Zip Code)

     

    (314) 678-6100

     

    (Registrant’s Telephone Number, Including Area Code)

     

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Securities registered pursuant to Section 12(b) of the Act: ☐

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STXS   NYSE American LLC

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition

     

    On August 7, 2025, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2025 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.

     

    Forward-Looking Statements and Additional Information

     

    Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

     

    In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits.    
         
    99.1   Stereotaxis, Inc. Earnings Press Release dated August 7, 2025.
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      STEREOTAXIS, INC.
         
    Date: August 7, 2025 By: /s/ Kimberly R. Peery
      Name: Kimberly R. Peery
      Title: Chief Financial Officer

     

     

     

    Get the next $STXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STXS

    DatePrice TargetRatingAnalyst
    1/10/2024$5.00Buy
    ROTH MKM
    7/12/2022$6.00Buy
    Aegis Capital
    6/23/2022$6.00Buy
    B. Riley Securities
    1/5/2022$11.00Buy
    Craig-Hallum
    1/5/2022$13.00Buy
    Loop Capital
    More analyst ratings

    $STXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shamir Nachum was granted 43,668 shares, increasing direct ownership by 96% to 89,276 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    7/3/25 4:05:24 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Benfer David was granted 43,668 shares, increasing direct ownership by 10% to 468,924 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    7/3/25 4:05:27 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Levin Ross B was granted 43,668 shares, increasing direct ownership by 9% to 531,197 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    7/3/25 4:05:30 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Stereotaxis with a new price target

    ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00

    1/10/24 8:16:33 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aegis Capital initiated coverage on Stereotaxis with a new price target

    Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

    7/12/22 9:20:32 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Stereotaxis with a new price target

    B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

    6/23/22 8:13:15 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter

    ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world's first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey. "We're excited to be the first to demonstrate the value of robotic high-density mapping and to offer this important innovation to our patients," said Dr. Corbisiero, Chief of Electrophysiology at

    9/2/25 8:08:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis to Present at Upcoming Investor Conferences

    ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. H.C. Wainwright 27th Annual Global Investment ConferenceMr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings. Lake Street Capital 9th Annual Best Ideas Growth ConferenceMr. Fischel will be available for one-on-one meetings on Thursday, September 11, 2025.

    9/2/25 7:51:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

    ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,

    8/28/25 7:47:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/11/25 3:38:02 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/10/25 10:32:20 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    8/20/24 8:38:24 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    SEC Filings

    View All

    SEC Form 424B5 filed by Stereotaxis Inc.

    424B5 - Stereotaxis, Inc. (0001289340) (Filer)

    8/29/25 5:26:30 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Stereotaxis, Inc. (0001289340) (Filer)

    8/29/25 5:00:59 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Stereotaxis Inc.

    10-Q - Stereotaxis, Inc. (0001289340) (Filer)

    8/13/25 3:00:57 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Leadership Updates

    Live Leadership Updates

    View All

    Stereotaxis Technology to be Featured at Heart Rhythm Society's HRX 2025

    ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,

    8/28/25 7:47:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

    ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The

    10/21/24 8:41:13 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

    ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti

    7/18/24 4:13:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Financials

    Live finance-specific insights

    View All

    Stereotaxis Reports 2025 Second Quarter Financial Results

    ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a

    8/7/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

    ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2025 financial results conference call  When:Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (Interna

    7/23/25 8:00:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stereotaxis Reports 2025 First Quarter Financial Results

    ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

    5/12/25 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/24 4:26:22 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/23 4:32:50 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

    SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

    2/14/22 5:07:16 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care